Cargando…
Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
To perform this meta-analysis, we investigated the risk of the most clinically relevant adverse events related to antivascular endothelial growth factor receptor (VEGFR) agents in advanced nonsmall-cell lung cancer (NSCLC). A comprehensive literature search for studies published up to October 2015 w...
Autores principales: | Gu, Biao, Gao, WenChuang, Chu, HongJun, Gao, Jian, Fu, Zhi, Ding, Hui, Lv, JunJie, Wu, QingQuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134808/ https://www.ncbi.nlm.nih.gov/pubmed/27902583 http://dx.doi.org/10.1097/MD.0000000000003752 |
Ejemplares similares
-
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
por: Ding, Lin, et al.
Publicado: (2016) -
Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015) -
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression
por: An, Na, et al.
Publicado: (2016) -
Skeletal-related events and overall survival of patients with bone metastasis from nonsmall cell lung cancer – A retrospective analysis
por: Kong, Pengyu, et al.
Publicado: (2017) -
Association of the VEGFR2 single nucleotide polymorphism rs2305948 with glioma risk
por: Sun, Shushu, et al.
Publicado: (2022)